AC
STLN

Aristeia Capital’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Aristeia Capital’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-62,500
Closed -$622K – 550
2021
Q2 		$622K Buy
+62,500
New +$629K 0.01% 375

Other funds holding STLN

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Aristeia Capital's STLN Position: Q3 2021 in Review

Aristeia Capital sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q3 2021, closing a stake of 62,500 shares — an estimated $622K sold.

Aristeia Capital first reported a position in STLN in Q2 2021 and held it in 1 quarter. The position peaked at $622K in Q2 2021. 51 funds tracked by Wall St. Rank hold STLN as of Q3 2021.

  • Aristeia Capital reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Aristeia Capital sold 62,500 Starling Oncology Institute, Inc. Common Stock shares in Q3 2021, an estimated $622K.
  • Aristeia Capital first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Aristeia Capital's Starling Oncology Institute, Inc. Common Stock position peaked at $622K in Q2 2021.
  • 51 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q3 2021.

Based on Aristeia Capital's 13F filing for Q3 2021, filed 15 Nov 2021.